The role of opioidergic genes in the treatment outcome of drug addiction pharmacotherapy: A systematic review

American Journal on Addictions

Volumn 24, Issue 1, 2015, Pages 15-23

  Bauer, Isabelle E ^a   Soares, Jair C ^a   Nielsen, David A ^b  

^a UNIVERSITY OF TEXAS   (United States)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3ALPHA HYDROXY 5ALPHA PREGNAN 20 ONE; ALCOHOL; BETA ENDORPHIN; BUPRENORPHINE PLUS NALOXONE; COCAINE; DELTA OPIATE RECEPTOR; KAPPA OPIATE RECEPTOR; METHADONE; MU OPIATE RECEPTOR; NALTREXONE; OPIATE; OPIATE ANTAGONIST; PSYCHOTROPIC AGENT; VACCINE; OPIATE RECEPTOR;

ALCOHOL CONSUMPTION; ALCOHOLISM; COCAINE DEPENDENCE; COGNITIVE THERAPY; DNA POLYMORPHISM; DRINKING BEHAVIOR; GENE FREQUENCY; GENE FUNCTION; GENETIC VARIABILITY; HAPLOTYPE; HEROIN DEPENDENCE; HETEROZYGOTE; HUMAN; MAJOR DEPRESSION; MEDLINE; METHADONE TREATMENT; MOOD DISORDER; OPIATE ADDICTION; PATIENT CARE; PHARMACOGENETICS; REVIEW; SCHIZOPHRENIA; SCOPUS; SELF REPORT; SYSTEMATIC REVIEW; TREATMENT OUTCOME; TREATMENT RESPONSE; COCAINE-RELATED DISORDERS; GENETIC POLYMORPHISM; GENETICS; OPIOID-RELATED DISORDERS;

ALCOHOLISM; COCAINE-RELATED DISORDERS; HUMANS; OPIOID-RELATED DISORDERS; POLYMORPHISM, GENETIC; RECEPTORS, OPIOID; TREATMENT OUTCOME;

EID: 84961288646     PISSN: 10550496     EISSN: 15210391     Source Type: Journal    
DOI: 10.1111/ajad.12172     Document Type: Review

References (52)

1. SAHMSA, Results from the 2012 National Survey on Drug Use and Health: Summary of National findings, N.S. H-46, Editor. 2013: Rockville, MD.
2. Kreek MJ, Nielsen DA, Butelman ER, et al. Genetic influences on impulsivity, risk taking, stress responsivity and vulnerability to drug abuse and addiction. Nat Neurosci, 2005; 8: 1450-1457.
3. Kreek MJ, Bart G, Lilly C, et al. Pharmacogenetics and human molecular genetics of opiate and cocaine addictions and their treatments. Pharmacol Rev, 2005; 57: 1-26.
4. Trigo JM, Martin-García E, Berrendero F, et al. The endogenous opioid system: A common substrate in drug addiction. Drug and Alcohol Dependence, 2010; 108: 183-194.
5. Makris N, Oscar-Berman M, Jaffin SK, et al. Decreased Volume of the Brain Reward System in Alcoholism. Biological Psychiatry, 2008; 64: 192-202.
6. Heilig M, Goldman D, Berrettini W, et al. Pharmacogenetic approaches to the treatment of alcohol addiction. Nat Rev Neurosci, 2011; 12: 670-684.
7. Li Z, Zhang H,. Analyzing interaction of μ-, δ-and κ-opioid receptor gene variants on alcohol or drug dependence using a pattern discovery-based method. J Addict Res Ther S, 2013; 7: 2.
8. Crist RC, Berrettini WH,. Pharmacogenetics of OPRM1. Pharmacology Biochemistry and Behavior, 2014; 123.
9. Bond C, LaForge KS, Tian M, et al. Single-nucleotide polymorphism in the human mu opioid receptor gene alters beta-endorphin binding and activity: possible implications for opiate addiction. Proc Natl Acad Sci USA, 1998; 95: 9608-9613.
10. Ray LA, Hutchison KE,. A polymorphism of the mu-opioid receptor gene (OPRM1) and sensitivity to the effects of alcohol in humans. Alcohol Clin Exp Res, 2004; 28: 1789-1795.
11. Tan EC, Tan CH, Karupathivan U, et al. Mu opioid receptor gene polymorphisms and heroin dependence in Asian populations. Neuroreport, 2003; 14: 569-572.
12. Clarke T-K, Crist RC, Kampman KM, et al. Low frequency genetic variants in the μ-opioid receptor (OPRM1) affect risk for addiction to heroin and cocaine. Neuroscience Letters, 2013; 542: 71-75.
13. Arias AJ, Armeli S, Gelernter J, et al. Effects of opioid receptor gene variation on targeted nalmefene treatment in heavy drinkers. Alcoholism: Clinical and Experimental Research, 2008; 32: 1159-1166.
14. Ramchandani VA, Umhau J, Pavon FJ, et al. A genetic determinant of the striatal dopamine response to alcohol in men. Mol Psychiatry, 2011; 16: 809-817.
15. Zhang H, Kranzler HR, Yang BZ, et al. The OPRD1 and OPRK1 loci in alcohol or drug dependence: OPRD1 variation modulates substance dependence risk. Mol Psychiatry, 2008; 13: 531-543.
16. Crist RC, Clarke TK, Ang A, et al. An Intronic Variant in OPRD1 Predicts Treatment Outcome for Opioid Dependence in African-Americans. Neuropsychopharmacology, 2013; 39: 1039.
17. Gupta A, Mulder J, Gomes I, et al. Increased abundance of opioid receptor heteromers after chronic morphine administration. Sci Signal, 2010; 3: ra54.
18. Nitsche JF, Schuller AG, King MA, et al. Genetic dissociation of opiate tolerance and physical dependence in delta-opioid receptor-1 and preproenkephalin knock-out mice. J Neurosci, 2002; 22: 10906-10913.
19. Filliol D, Ghozland S, Chluba J, et al. Mice deficient for delta- and mu-opioid receptors exhibit opposing alterations of emotional responses. Nat Genet, 2000; 25: 195-200.
20. Zhang H, Kranzler H, Yang B, et al. The OPRD1 and OPRK1 loci in alcohol or drug dependence: OPRD1 variation modulates substance dependence risk. Molecular psychiatry, 2008; 13: 531-543.
21. Nelson EC, Lynskey MT, Heath AC, et al. Association of OPRD1 polymorphisms with heroin dependence in a large case-control series. Addiction biology, 2014; 19: 111-121.
22. Crist RC, Ambrose-Lanci LM, Vaswani M, et al. Case-control association analysis of polymorphisms in the delta-opioid receptor, OPRD1, with cocaine and opioid addicted populations. Drug and Alcohol Dependence, 2013; 127: 122-128.
23. Tejeda HA, Shippenberg TS, Henriksson R,. The dynorphin/kappa-opioid receptor system and its role in psychiatric disorders. Cell Mol Life Sci, 2012; 69: 857-896.
24. Unterwald EM, Rubenfeld JM, Kreek MJ,. Repeated cocaine administration upregulates kappa and mu, but not delta, opioid receptors. Neuroreport, 1994; 5: 1613-1616.
25. McLaughlin JP, Marton-Popovici M, Chavkin C,. Kappa opioid receptor antagonism and prodynorphin gene disruption block stress-induced behavioral responses. J Neurosci, 2003; 23: 5674-5683.
26. Xuei X, Dick D, Flury-Wetherill L, et al. Association of the kappa-opioid system with alcohol dependence. Mol Psychiatry, 2006; 11: 1016-1024.
27. Wang S-C, Tsou H-H, Chung R-H, et al. The Association of Genetic Polymorphisms in the κ-Opioid Receptor 1 Gene With Body Weight, Alcohol Use, and Withdrawal Symptoms in Patients With Methadone Maintenance. Journal of clinical psychopharmacology, 2014; 34: 205-211.
28. Levran O, Londono D, O'Hara K, et al. Genetic susceptibility to heroin addiction: a candidate gene association study. Genes, Brain and Behavior, 2008; 7: 720-729.
29. Xu K, Seo D, Hodgkinson C, et al. A variant on the kappa opioid receptor gene (OPRK1) is associated with stress response and related drug craving, limbic brain activation and cocaine relapse risk. Translational psychiatry, 2013; 3: e292.
30. Drobes DJ, Anton RF, Thomas SE, et al. Effects of naltrexone and nalmefene on subjective response to alcohol among non-treatment-seeking alcoholics and social drinkers. Alcohol Clin Exp Res, 2004; 28: 1362-1370.
31. O'Malley SS, Krishnan-Sarin S, Farren C, et al. Naltrexone decreases craving and alcohol self-administration in alcohol-dependent subjects and activates the hypothalamo-pituitary-adrenocortical axis. Psychopharmacology (Berl), 2002; 160: 19-29.
32. Kiefer F, Jahn H, Tarnaske T, et al. Comparing and combining naltrexone and acamprosate in relapse prevention of alcoholism: a double-blind, placebo-controlled study. Arch Gen Psychiatry, 2003; 60: 92-99.
33. Anton RF, Drobes DJ, Voronin K, et al. Naltrexone effects on alcohol consumption in a clinical laboratory paradigm: temporal effects of drinking. Psychopharmacology (Berl), 2004; 173: 32-40.
34. Ray LA, Hutchison KE,. Effects of naltrexone on alcohol sensitivity and genetic moderators of medication response: a double-blind placebo-controlled study. Arch Gen Psychiatry, 2007; 64: 1069-1077.
35. Kim SG, Kim CM, Choi SW, et al. A micro opioid receptor gene polymorphism (A118G) and naltrexone treatment response in adherent Korean alcohol-dependent patients. Psychopharmacology (Berl), 2009; 201: 611-618.
36. McGeary JE, Monti PM, Rohsenow DJ, et al. Genetic moderators of naltrexone's effects on alcohol cue reactivity. Alcohol Clin Exp Res, 2006; 30: 1288-1296.
37. Oslin DW, Berrettini W, Kranzler HR, et al. A functional polymorphism of the mu-opioid receptor gene is associated with naltrexone response in alcohol-dependent patients. Neuropsychopharmacology, 2003; 28: 1546-1552.
38. Anton RF, Oroszi G, O'Malley S, et al. An evaluation of mu-opioid receptor (OPRM1) as a predictor of naltrexone response in the treatment of alcohol dependence: results from the Combined Pharmacotherapies and Behavioral Interventions for Alcohol Dependence (COMBINE) study. Arch Gen Psychiatry, 2008; 65: 135-144.
39. Oroszi G, Anton RF, O'Malley S, et al. OPRM1 Asn40Asp Predicts Response to Naltrexone Treatment: A Haplotype-Based Approach. Alcoholism: Clinical and Experimental Research, 2009; 33: 383-393.
40. Ray LA, Bujarski S, Chin PF, et al. Pharmacogenetics of naltrexone in Asian Americans: a randomized placebo-controlled laboratory study. Neuropsychopharmacology, 2011; 37: 445-455.
41. Ray LA, Hutchison KE, Ashenhurst JR, et al. Naltrexone selectively elevates GABAergic neuroactive steroid levels in heavy drinkers with the Asp40 allele of the OPRM1 gene: a pilot investigation. Alcoholism: Clinical and Experimental Research, 2010; 34: 1479-1487.
42. O'Malley SS, Robin RW, Levenson AL, et al. Naltrexone Alone and With Sertraline for the Treatment of Alcohol Dependence in Alaska Natives and Non-Natives Residing in Rural Settings: A Randomized Controlled Trial. Alcoholism: Clinical and Experimental Research, 2008; 32: 1271-1283.
43. Tidey JW, Monti PM, Rohsenow DJ, et al. Moderators of Naltrexone's Effects on Drinking, Urge, and Alcohol Effects in Non-Treatment-Seeking Heavy Drinkers in the Natural Environment. Alcoholism: Clinical and Experimental Research, 2008; 32: 58-66.
44. Gelernter J, Gueorguieva R, Kranzler HR, et al. Opioid receptor gene (OPRM1, OPRK1, and OPRD1) variants and response to naltrexone treatment for alcohol dependence: results from the VA Cooperative Study. Alcoholism: Clinical and Experimental Research, 2007; 31: 555-563.
45. Clarke T, Crist R, Ang A, et al. Genetic variation in OPRD1 and the response to treatment for opioid dependence with buprenorphine in European-American females. The pharmacogenomics journal, 2013; 14: 303-308.
46. Levran O, Peles E, Randesi M, et al. Association of genetic variation in pharmacodynamic factors with methadone dose required for effective treatment of opioid addiction. Pharmacogenomics, 2013; 14: 755-768.
47. Wang S-C, Tsou H-H, Chen C-H, et al. Genetic polymorphisms in the opioid receptor mu1 gene are associated with changes in libido and insomnia in methadone maintenance patients. European Neuropsychopharmacology, 2012; 22: 695-703.
48. Hung C-C, Chiou M-H, Huang B-H, et al. Impact of genetic polymorphisms in ABCB1, CYP2B6, OPRM1, ANKK1 and DRD2 genes on methadone therapy in Han Chinese patients. Pharmacogenomics, 2011; 12: 1525-1533.
49. Coller JK, Cahill S, Edmonds C, et al. OPRM1 A118G genotype fails to predict the effectiveness of naltrexone treatment for alcohol dependence. Pharmacogenetics and genomics, 2011; 21: 902-905.
50. Crettol S, Besson J, Croquette-Krokar M, et al. Association of dopamine and opioid receptor genetic polymorphisms with response to methadone maintenance treatment. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2008; 32: 1722-1727.
51. Martell BA, Mitchell E, Poling J, et al. Vaccine pharmacotherapy for the treatment of cocaine dependence. Biol Psychiatry, 2005; 58: 158-164.
52. Nielsen DA, Hamon S, Kosten TR,. The K-opioid receptor gene as a predictor of response in a cocaine vaccine trial. Psychiatr Genet, 2013; 23: 225-232.